Abstract 50P
Background
Breast Cancer is the most diagnosed cancer type worldwide and the second leading cause of cancer-related deaths among women. Anti-HER2 treatment has shifted the treatment paradigm of HER2-positive tumors. Historically, only breast cancer patients with HER2 IHC score of 3+ or with HER2 gene (FISH) amplification have benefited from anti-HER2 agents. However, emerging evidence suggests that even a minimal amplification of HER2 may significantly impact response to therapy and prognosis. This led to the introduction of the new concept of HER2-low breast cancers. Our retrospective analysis aims to unveil the impact of HER2 low expression on the response to neoadjuvant chemotherapy (NACT) in non-metastatic HER2-negative breast cancers.
Methods
All patients’ profiles with non-metastatic, HER2-negative breast cancers who received neo-adjuvant chemotherapy and underwent surgery between the 1st of January 2018 and the 30th of August 2022 were retrospectively reviewed. Patients were stratified into HER2-low and HER2-negative groups based on IHC score and FISH amplification. To compare the two study groups, patients’ response was clinically evaluated using surgical pathology reports. The primary endpoint was the response to NACT reported as the objective response rate (ORR) of HER2-low and HER2-negative tumors.
Results
Out of 262 patients, 236 patients had a response. Among the responders, 32 patients (14%) in the HER2-low group had a complete response compared to 4 patients (14%) in the HER2-negative group, OR 0.7 (95% CI:0.2 – 3), p-value= 0.6. While 132 patients (57%) and 17 patients (59%) had a partial response in the HER2-low and HER2-negative groups respectively, OR 0.7 (95% CI:0.2 – 2), p-value= 0.5. Across both groups, more patients with hormone-positive tumors had a response compared to hormone-negative tumors (p-value=0.01).
Conclusions
Preliminary results did not show any statistically significant impact of HER2 low expression on neoadjuvant chemotherapy response. Nonetheless, statistical significance was observed relative to hormone expression, in accordance with the published literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center, Hamad Medical Corporation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract